stable disease
Pts with RECIST response continued on open-label B, those with progressive disease (PD) went off study, and those with stable disease (SD) were randomized 1:1 to B or placebo (P), stratified by FGF2 expression (IHC + or -), until PD or unacceptable toxicity.